L Raoux1, C Maulat2, F-Z Mokrane3, N Fares4, B Suc1, F Muscari1. 1. Digestive Surgery and Liver Transplantation Department, Toulouse-Rangueil University Hospital, CHU Rangueil, 1, avenue du Pr. Jean-Poulhès, 31059 Toulouse cedex 9, France. 2. Digestive Surgery and Liver Transplantation Department, Toulouse-Rangueil University Hospital, CHU Rangueil, 1, avenue du Pr. Jean-Poulhès, 31059 Toulouse cedex 9, France. Electronic address: charlotte.maulat@gmail.com. 3. Department of Radiology, Toulouse-Rangueil University Hospital, 1, avenue du Pr. Jean-Poulhès, 31059 Toulouse cedex 9, France. 4. Department of Oncology, Toulouse-Rangueil University Hospital, 1 avenue du Pr. Jean-Poulhès, 31059 Toulouse cedex 9, France.
Abstract
AIM OF THE STUDY: Fourteen to seventeen percent of patients suffering from colorectal cancer have synchronous liver metastases (sCRLM) at the time of diagnosis. There are currently three possible strategies for curative management of sCRLM: "classic", "combined", and "liver-first". The aim of our research was to analyze the effects of the three surgical management strategies for sCRLM on postoperative morbidity and mortality and overall and recurrence-free survival. PATIENTS AND METHODS: Patients treated for sCRLM between October 2000 and May 2015 were included. We defined three groups: (1) "classic": surgery of primary tumor and then surgery of sCRLM; (2) "combined": combined surgery of primary tumor and sCRLM: and (3) "liver-first": surgery of sCRLM and then surgery of primary tumor. RESULTS: During this period, 170 patients who underwent 209 hepatectomies were included ("classic": 149, "combined": 34, "liver-first": 26). The rate of severe complications was higher in the "combined" group compared to the "classic" group (35% vs. 12%, P=0.03), and the "liver-first" group (35% vs. 19%, P=0.25), while there were significantly fewer liver resections. Overall survival at 5 years in our cohort was 46%, without significant differences between the groups, and a median survival of 54 months. Recurrence-free survival of the patients in our cohort was 24% at 5 years, with a median survival time without recurrence of 14 months, without significant differences between the groups. CONCLUSION: All three strategies were feasible and there were no differences regarding overall and recurrence-free survivals between the three approaches. The "combined" strategy group had significantly more severe complications and did not provide better oncological results, despite less aggressive liver disease and more limited liver resections.
AIM OF THE STUDY: Fourteen to seventeen percent of patients suffering from colorectal cancer have synchronous liver metastases (sCRLM) at the time of diagnosis. There are currently three possible strategies for curative management of sCRLM: "classic", "combined", and "liver-first". The aim of our research was to analyze the effects of the three surgical management strategies for sCRLM on postoperative morbidity and mortality and overall and recurrence-free survival. PATIENTS AND METHODS: Patients treated for sCRLM between October 2000 and May 2015 were included. We defined three groups: (1) "classic": surgery of primary tumor and then surgery of sCRLM; (2) "combined": combined surgery of primary tumor and sCRLM: and (3) "liver-first": surgery of sCRLM and then surgery of primary tumor. RESULTS: During this period, 170 patients who underwent 209 hepatectomies were included ("classic": 149, "combined": 34, "liver-first": 26). The rate of severe complications was higher in the "combined" group compared to the "classic" group (35% vs. 12%, P=0.03), and the "liver-first" group (35% vs. 19%, P=0.25), while there were significantly fewer liver resections. Overall survival at 5 years in our cohort was 46%, without significant differences between the groups, and a median survival of 54 months. Recurrence-free survival of the patients in our cohort was 24% at 5 years, with a median survival time without recurrence of 14 months, without significant differences between the groups. CONCLUSION: All three strategies were feasible and there were no differences regarding overall and recurrence-free survivals between the three approaches. The "combined" strategy group had significantly more severe complications and did not provide better oncological results, despite less aggressive liver disease and more limited liver resections.
Authors: Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu Journal: World J Urol Date: 2022-10-02 Impact factor: 3.661
Authors: Wang Da; Wu Yinhang; Zhuang Jing; Xu Jiamin; Gao Xinyi; Song Yongmao; Pan Yuefen Journal: J Interferon Cytokine Res Date: 2022-05 Impact factor: 3.657
Authors: Felice Giuliante; Luca Viganò; Agostino M De Rose; Darius F Mirza; Réal Lapointe; Gernot Kaiser; Eduardo Barroso; Alessandro Ferrero; Helena Isoniemi; Santiago Lopez-Ben; Irinel Popescu; Jean-Francois Ouellet; Catherine Hubert; Jean-Marc Regimbeau; Jen-Kou Lin; Oleg G Skipenko; Francesco Ardito; René Adam Journal: Ann Surg Oncol Date: 2021-07-01 Impact factor: 5.344